Literature DB >> 8435476

Type IV collagenases in invasive tumors.

K Tryggvason1, M Höyhtyä, C Pyke.   

Abstract

The matrix metalloproteinases appear to be elevated in tumors with metastatic potential, and may well be involved in penetration of the basement membrane and degradation of extracellular proteins including type IV collagen. An imbalance between the 72 kDa and 92 kDa type IV collagenases and the associated tissue inhibitors of these metalloproteinases (TIMPs) may therefore have a role in the invasive phenotype. Cultured tumor cells with invasive potential secrete both type IV collagenases, though in tumors there is some evidence that the 72 kDa form at least may be produced by stromal cells at the invading tumor front rather than primarily by the tumor cells themselves, while the 92 kDa form may be synthesized in macrophages near the front. These collagenases are elevated in invasive as compared with in situ tumor components, but their specific roles and prognostic significance are not yet established.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435476     DOI: 10.1007/bf01833261

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  46 in total

1.  Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression.

Authors:  A D'Errico; S Garbisa; L A Liotta; V Castronovo; W G Stetler-Stevenson; W F Grigioni
Journal:  Mod Pathol       Date:  1991-03       Impact factor: 7.842

2.  Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells.

Authors:  H Ura; R D Bonfil; R Reich; R Reddel; A Pfeifer; C C Harris; A J Klein-Szanto
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

3.  The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation.

Authors:  W G Stetler-Stevenson; H C Krutzsch; M P Wacher; I M Margulies; L A Liotta
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

4.  The activation of human skin fibroblast procollagenase. Sequence identification of the major conversion products.

Authors:  G A Grant; A Z Eisen; B L Marmer; W T Roswit; G I Goldberg
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

5.  Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase.

Authors:  M S Hibbs; K A Hasty; J M Seyer; A H Kang; C L Mainardi
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

6.  Characterization of the procollagen IV cleavage products produced by a specific tumor collagenase.

Authors:  L I Fessler; K G Duncan; J H Fessler; T Salo; K Tryggvason
Journal:  J Biol Chem       Date:  1984-08-10       Impact factor: 5.157

7.  Purification and properties of a small latent matrix metalloproteinase of the rat uterus.

Authors:  J F Woessner; C J Taplin
Journal:  J Biol Chem       Date:  1988-11-15       Impact factor: 5.157

8.  Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells.

Authors:  P Huhtala; A Tuuttila; L T Chow; J Lohi; J Keski-Oja; K Tryggvason
Journal:  J Biol Chem       Date:  1991-09-05       Impact factor: 5.157

9.  Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors.

Authors:  H Autio-Harmainen; T Karttunen; T Hurskainen; M Höyhtyä; A Kauppila; K Tryggvason
Journal:  Lab Invest       Date:  1993-09       Impact factor: 5.662

10.  Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro.

Authors:  C M Alexander; Z Werb
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

View more
  62 in total

1.  Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion.

Authors:  H Nakahara; L Howard; E W Thompson; H Sato; M Seiki; Y Yeh; W T Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer.

Authors:  Lin-Bo Wang; Zhi-Nong Jiang; Miao-Ying Fan; Chao-Yang Xu; Wen-Jun Chen; Jian-Guo Shen
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

3.  Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma.

Authors:  Y Kitadai; L M Ellis; S L Tucker; G F Greene; C D Bucana; K R Cleary; Y Takahashi; E Tahara; I J Fidler
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

4.  Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis.

Authors:  P Liokumovich; I Goldberg; B Davidson; W H Gotlieb; T Zahavi; G Ben-Baruch; I Reder; J Kopolovic
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

Review 5.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

6.  Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: correlation with tumour growth.

Authors:  Annette Lebeau; Claudia Müller-Aufdemkamp; Clarissa Allmacher; Ulrich Sauer; Andreas Nerlich; Ralf Lichtinghagen; Udo Löhrs
Journal:  J Mol Histol       Date:  2004-06       Impact factor: 2.611

7.  Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.

Authors:  T Kirkegaard; A Hansen; E Bruun; J Brynskov
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

8.  Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.

Authors:  H Zhang; T Morisaki; H Matsunaga; N Sato; A Uchiyama; K Hashizume; F Nagumo; J Tadano; M Katano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

9.  Matrix metalloproteinases and their inhibitors in gastric cancer.

Authors:  G I Murray; M E Duncan; E Arbuckle; W T Melvin; J E Fothergill
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

10.  MT-MMP expression and localisation in human lung and breast cancers.

Authors:  M Polette; B Nawrocki; C Gilles; H Sato; M Seiki; J M Tournier; P Birembaut
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.